Table 2.
Maximum relaxation (E max ) and potency (pD 2 ) observed with non-selective TAS2R agonists and reference relaxing agents (isoproterenol, formoterol and theophylline) on human bronchi
| E max (%) | pD 2 | n | |
|---|---|---|---|
|
Control |
15.0 ± 3.5 |
NA |
11 |
|
Chloroquine |
94.2 ± 2.3 |
4.2 ± 0.1 |
10-24 |
|
Quinine |
89.5 ± 3.0 |
3.7 ± 0.2 |
9 |
|
Caffeine |
75.6 ± 6.3 |
3.7 ± 0.3 |
11 |
|
Strychnine |
68.7 ± 7.8 |
4.0 ± 0.4 |
10 |
|
Diphenidol |
65.9 ± 9.0 |
4.6 ± 0.4 |
11 |
|
Denatonium |
38.6 ± 3.6 |
NA |
11 |
|
Saccharin |
27.6 ± 5.5 |
NA |
10 |
|
Ofloxacin |
21.9 ± 5.1 |
NA |
11 |
|
Colchicine |
18.3 ± 3.7 |
NA |
10 |
|
Isoproterenol |
99.8 ± 0.2 |
7.7 ± 0.1 |
11 |
|
Formoterol |
75.9 ± 5.0 |
8.9 ± 0.2 |
11 |
| Theophylline | 100.0 ± 0.0 | 3.9 ± 0.1 | 10 |
Emax values are expressed as a percentage of the relaxation observed with 3 mM theophylline (mean ± SEM of experiments performed on isolated bronchi from n distinct patients).